MedTrace Logo

Genetics of Cytochrome CYP2D6 and Effects of Codeine and Tramadol on Postoperative Pain Management

NCT06723379 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 22

Last updated 2024-12-09

No results posted yet for this study

Summary

Codeine is one of the most commonly prescribed opioids in the world. The speed at which our liver metabolizes codeine into morphine depends on an important protein called cytochrome P450 2D6 (CYP2D6). Many people across the world have different CYP2D6 metabolizing speeds. Codeine provides inadequate pain management to those who have slow-metabolizing CYP2D6. In contrast, codeine can be life-threatening to those who have rapidly-metabolizing CYP2D6 because of the abruptly high dose of morphine. By analyzing specific genes, we are able to predict a patient's response to medication, thus drug type and dosing can be tailored according to their genetics. The purpose of this study is to observe if nanopore CYP2D6 DNA genetic sequencing can classify patients according to their CYP2D6 phenotype and thus predict their response to codeine and tramadol. The overall project is to determine the practicality of a genetic survey of CYP2D6 for healthy patients undergoing surgical procedures.

Conditions

  • Post-operative Pain

Sponsors & Collaborators

  • University of British Columbia

    collaborator OTHER

  • Fraser Health

    lead OTHER

Principal Investigators

  • Perseus Missirlis, MSc, MD · Fraser Health

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2022-11-25
Primary Completion
2024-07-10
Completion
2024-12-01

Countries

  • Canada

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06723379 on ClinicalTrials.gov